Biotech Values

[ghmm]

Orphan Pricing:

Its hard to tell what figure you would deem acceptable and what would not be. If you are OK with say a $250k figure across the board I would grant that quite a few orphan indications we have drugs for would still exist... though many that are now getting some effort may not (e.g. Batten disease).

I don't think tax credits are enough incentive. To me the Orphan drug exclusivity was one of the best initiatives to provide incentive (though I think you still need a fairly high price too). If one wants to come up with some other creative ways to keep prices down and still create incentive perhaps something along the lines of the priority review voucher (though make more valuable like giving an extra period for NCE exclusivity with some reasonable limit to it being applied for the same NCE).